May 17, 2020

Swift Shift launches re-engagement platform Boost to support home healthcare recruitment

Technology
healthcare services
USA
healthcare services
Catherine Sturman
3 min
healthcare at home (Getty Images)
Founded in 2014, Swift Shift, a HIPAA-compliant workforce recruitment and management platform for home healthcare enterprises, connects home healthcare...

Founded in 2014, Swift Shift, a HIPAA-compliant workforce recruitment and management platform for home healthcare enterprises, connects home healthcare providers with qualified caregivers and nurses to address the national nursing shortage.

Raising $5.7 million in funding. Swift Shift’s mobile-first workforce management platform for the home healthcare industry, named Boost, will provide a recruitment solution for home healthcare agencies by addressing the nursing shortage. Boost helps agencies re-engage their inactive workforce with targeted, relevant cases, thereby shortening the recruitment funnel.

The US is facing a critical nurse and caregiver shortage, with demand for nurses expected to reach 1.6 million by 2020, as an increase of geriatric and pediatric patients requiring care grows simultaneously. Recruiting new, qualified nurses is essential, but also expensive, costing up to $3,000 per each successful recruit.

By shifting the focus from job boards, digital ads, and other less targeted approaches to recruitment, Swift Shift’s Boost opens new pathways for agencies and nurses to connect based on value and relevance. 53% of the $3 billion spent on recruitment in home healthcare is allocated to re-engage nurses and caregivers who have already been recruited, vetted, and hired and have since become inactive. This leaves only 47% of home healthcare recruitment budgets attributing to net growth.

Lack of transparency about case allocation and long recruitment processes account for 50% of the drop off in candidates. Through Boost, nurses and caregivers now discover available cases according to their work preferences, skill set, available hours, and location. Convenience and earnings are maximised for applicants with faster approval times through on-demand, in-app applications.

See also

“We spent two years studying the recruitment metrics and challenges of Home Healthcare agencies and another year building a platform that delivers both what nurses and caregivers are looking for and also increases the productivity of recruiters,” said Assaf Shalvi, CEO and Founder of Swift Shift.

“The best operators in the Home Healthcare market realise that their growth is dependent on their ability to hire and retain staff. Boost is a tool that is built to deliver exactly that.”

Value for Home Healthcare Agencies


Swift Shift Boost reduces recruitment costs and increases nurse lifetime value by:

  • Decreasing time spent screening applicants and higher conversions with targeted cases to relevant candidates
  • Shortening recruitment funnel with rich, pre-vetted profiles that include experience, rating, certifications and endorsements
  • Reduces “bench time” once application is complete with one click approvals leading to work assignments in less than 24 hours
  • Longer tenures/higher retention of nurses with features such as in-app chat, multiple case application and management
  • Real-time operational data insights, empowering agencies to make data driven operational decisions
  • 100% success based recruitment tool is the first and only pay for performance model in the industry

Value for Nurses and Caregivers

Boost creates a meaningful engagement for nurses and caregivers by:

  • Reducing travel time and expenses with location-based technology
  • Enabling nurses and caregivers to control their work schedule from a mobile-app
  • Offering in-app messaging to streamline communication with agencies
  • Empowering nurses and caregivers to apply for jobs that they actually want

The nurse-facing mobile app leverages cloud technology. Clients include BAYADA Home Health Care, Interim HealthCare, Aveanna Healthcare, and more.

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

NHS
Cancer
immunotherapy
MachineLearning
2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article